Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review

Primož Strojan; Jan B. Vermorken; Jonathan J. Beitler; Nabil F. Saba; Missak Haigentz; Paolo Bossi; Francis P. Worden; Johannes A. Langendijk; Avraham Eisbruch; William M. Mendenhall; Anne W.M. Lee; Louis B. Harrison; Carol R. Bradford; Robert Smee; Carl E. Silver; Alessandra Rinaldo; Alfio Ferlito

doi:10.1002/hed.24026

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review

Primož Strojan, Jan B. Vermorken, Jonathan J. Beitler, Nabil F. Saba, Missak Haigentz, Paolo Bossi, Francis P. Worden, Johannes A. Langendijk, Avraham Eisbruch, William M. Mendenhall, Anne W.M. Lee, Louis B. Harrison, Carol R. Bradford, Robert Smee, Carl E. Silver, Alessandra Rinaldo, Alfio Ferlito

Medicine

Research output: Contribution to journal › Review article › peer-review

133 Scopus citations

Abstract

Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.

Original language	English (US)
Pages (from-to)	E2151-E2158
Journal	Head and Neck
Volume	38
DOIs	https://doi.org/10.1002/hed.24026
State	Published - Apr 1 2016

Keywords

cisplatin
concurrent chemoradiotherapy
cumulative dose
outcome
radiotherapy

ASJC Scopus subject areas

Otorhinolaryngology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/hed.24026

Cite this

Strojan, P., Vermorken, J. B., Beitler, J. J., Saba, N. F., Haigentz, M., Bossi, P., Worden, F. P., Langendijk, J. A., Eisbruch, A., Mendenhall, W. M., Lee, A. W. M., Harrison, L. B., Bradford, C. R., Smee, R., Silver, C. E., Rinaldo, A., & Ferlito, A. (2016). Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head and Neck, 38, E2151-E2158. https://doi.org/10.1002/hed.24026

Strojan, P, Vermorken, JB, Beitler, JJ, Saba, NF, Haigentz, M, Bossi, P, Worden, FP, Langendijk, JA, Eisbruch, A, Mendenhall, WM, Lee, AWM, Harrison, LB, Bradford, CR, Smee, R, Silver, CE, Rinaldo, A & Ferlito, A 2016, 'Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review', Head and Neck, vol. 38, pp. E2151-E2158. https://doi.org/10.1002/hed.24026

@article{f0017bd4d52c4934890d45d39067143a,

title = "Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review",

abstract = "Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.",

keywords = "cisplatin, concurrent chemoradiotherapy, cumulative dose, outcome, radiotherapy",

author = "Primo{\v z} Strojan and Vermorken, {Jan B.} and Beitler, {Jonathan J.} and Saba, {Nabil F.} and Missak Haigentz and Paolo Bossi and Worden, {Francis P.} and Langendijk, {Johannes A.} and Avraham Eisbruch and Mendenhall, {William M.} and Lee, {Anne W.M.} and Harrison, {Louis B.} and Bradford, {Carol R.} and Robert Smee and Silver, {Carl E.} and Alessandra Rinaldo and Alfio Ferlito",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc..",

year = "2016",

month = apr,

day = "1",

doi = "10.1002/hed.24026",

language = "English (US)",

volume = "38",

pages = "E2151--E2158",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer

T2 - A systematic review

AU - Strojan, Primož

AU - Vermorken, Jan B.

AU - Beitler, Jonathan J.

AU - Saba, Nabil F.

AU - Haigentz, Missak

AU - Bossi, Paolo

AU - Worden, Francis P.

AU - Langendijk, Johannes A.

AU - Eisbruch, Avraham

AU - Mendenhall, William M.

AU - Lee, Anne W.M.

AU - Harrison, Louis B.

AU - Bradford, Carol R.

AU - Smee, Robert

AU - Silver, Carl E.

AU - Rinaldo, Alessandra

AU - Ferlito, Alfio

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.

AB - Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.

KW - cisplatin

KW - concurrent chemoradiotherapy

KW - cumulative dose

KW - outcome

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84973472579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973472579&partnerID=8YFLogxK

U2 - 10.1002/hed.24026

DO - 10.1002/hed.24026

M3 - Review article

AN - SCOPUS:84973472579

SN - 1043-3074

VL - 38

SP - E2151-E2158

JO - Head and Neck

JF - Head and Neck

ER -

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this